Moderna’s stock doubles on promising cancer-vaccine results
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda. This story matters for Finance & Markets readers tracking expo. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. Expo-News curates and briefs the finance & markets stories that matter. Our editorial policy →